Milatuzumab

Source: Wikipedia, the free encyclopedia.
Milatuzumab
Humanized (from mouse)
TargetCD74
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6518H10066N1758O2020S40
Molar mass146658.91 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Milatuzumab (or hLL1) is an anti-CD74[1] humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia.[2][3]

The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.

Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).

CD74

CD74 is present on a variety of hematological tumors and even on some solid cancers. It is present in limited amounts in normal tissues but widely found in leukemias, lymphomas and the vast majority of multiple myeloma cases.[citation needed] CD74 is involved in a cell-to-cell communication pathway that is critical for survival.[citation needed] When CD74 is blocked by milatuzumab, it can lead to cell death.

CD74 is an attractive target for a drug conjugate because of its rapid internalizing property.[citation needed]

In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin,

antibody-drug conjugate
or ADC, have demonstrated anti-lymphoma activity in-vivo.

Antibody-drug Conjugates

IMMU-110

hLL1-Dox
Milatuzumab has been linked to
antibody-drug conjugate or ADC (known as hLL1-Dox or IMMU-110) for treatment of relapsed multiple myeloma. A Phase I/II clinical trial to evaluate this milatuzumab-doxorubicin conjugate began in 2010,[5][6] but was terminated in 2021 due to lack of efficacy.[7]

References

  1. S2CID 23818626
    .
  2. PMID 21228331
    .
  3. S2CID 207475327
    .
  4. ^ Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. P. Sapra, R. Stein, J. Pickett, Z. Qu, S.V. Govindan, T.M. Cardillo, H.J. Hansen, I.D. Horak, G.L. Griffiths, D.M. Goldenberg. Clin Cancer Res 11:5257-5264, 2005.
  5. ^ "Milatuzumab-Doxorubicin (IMMU-110 / hLL1-dox) Clinical Trials". ADC Review / Journal of Antibody-drug Conjugates.
  6. ^ "Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma". News Medical and Immunomedics Press Release. 16 June 2010.
  7. ^ Clinical trial number NCT01101594 for "A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma" at ClinicalTrials.gov
Retrieved from "https://en.wikipedia.org/w/index.php?title=Milatuzumab&oldid=1177181756"